Feb 18, 2026 09:05AM

Feb 9, 2026 09:20AM

Oct 14, 2025 09:46AM

May 12, 2025 07:08AM

Apr 24, 2025 09:09AM

Apr 9, 2025 08:30AM

Apr 8, 2025 11:21AM NeuroSense Therapeutics Ltd. (NRSN) Reports FY results

Jan 6, 2025 09:02AM

Dec 16, 2024 08:13AM

Dec 11, 2024 09:25AM

Dec 2, 2024 08:32AM

Nov 19, 2024 04:18PM

Oct 28, 2024 08:30AM

Oct 15, 2024 09:16AM Neurosense (NRSN) Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

Oct 9, 2024 09:02AM

Sep 24, 2024 09:05AM

Sep 24, 2024 09:00AM

Aug 30, 2024 04:30PM

Aug 7, 2024 02:00PM

Aug 1, 2024 09:15AM

Jul 9, 2024 09:27AM Neurosense's (NRSN) PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

Jul 1, 2024 08:07AM

Jun 21, 2024 04:30PM

Nov 28, 2022 11:26AM

353,174 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All